• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

ASCO 2024 and Beyond: Addressing NSCLC Unmet Needs and Future Research Directions

Opinion
Video

Jason Porter, MD, provides concluding insights on the LAURA phase 3 trial, CHRYSALIS-2 study, TROPION-Lung05 trial, and CheckMate 9LA study, along with other notable findings from the ASCO 2024 conference.

Video content above is prompted by the following questions:

  1. How do these four trials address the unmet needs of patients with NSCLC?
  2. After the presentation of advancements in NSCLC research at ASCO, how do you envision the future of personalized medicine in this disease?
  3. Please discuss any other data in NSCLC released at ASCO 2024 that you find noteworthy to share with colleagues.
  4. Outside of ASCO 2024, what ongoing research efforts are you most excited for in the treatment and management of NSCLC? What can we look forward to through the end of the year and beyond?
Related Videos
Ana Baramidze, MD
Ana Baramidze, MD
Dr Julia Rotow
Frank Weinberg, MD, PhD
Related Content
Lungs | Image credit: Rasi - stock.adobe.com

Stereotactic Body Radiation Therapy Equally Effective as Surgery in Stage I NSCLC

October 30th 2025
Article

Comparable overall survival and distant recurrence outcomes make stereotactic body radiation a feasible alternative.

Read More

Biopsy | Image credit: arcyto - stock.adobe.com

Increased Risk of Recurrence in NSCLC Found After Preoperative PTNB

October 15th 2025
Article

Individuals who had preoperative percutaneous transthoracic needle biopsy (PTNB) had an increased risk of local-regional recurrence in non–small cell lung cancer (NSCLC).

Read More

Quality of life | Image credit: Sandwish - stock.adobe.com

HRQOL Not Consistently Assessed in Studies on NSCLC Treatment Efficacy

October 8th 2025
Article

A review found that assessing for health-related quality of life (HRQOL) was not frequently done in studies related to non–small cell lung cancer (NSCLC).

Read More

Lung cancer | Image credit: appledesign - stock.adobe.com

Aumolertinib Effective in Treating EGFR-Mutant NSCLC

October 7th 2025
Article

Aumolertinib was compared against osimertinib to demonstrate its efficacy in those with mutated non-small cell lung cancer (NSCLC).

Read More

Doctor looking at x-ray on tablet | Image credit: steph photographies - stock.adobe.com

Discontinuation of ICIs Produced Similar Results Compared With Continuous Use in NSCLC

October 2nd 2025
Article

Adverse events related to the immune system tended to accumulate over time when patients used immune checkpoint inhibitors (ICIs) over time.

Read More

AJMC Q&A with Danny Nguyen, MD | Background image credit: ipopba - stock.adobe.com

Weighing Osimertinib vs Amivantamab-Lazertinib in Frontline EGFR NSCLC: Danny Nguyen, MD

October 1st 2025
Article

Amivantamab plus lazertinib enhances survival in NSCLC but requires complex care compared with osimertinib, explained Danny Nguyen, MD, of City of Hope.

Read More

© 2025 MJH Life Sciences
AJMC®
All rights reserved.